Levofloxacin
Antibiotic
General information
Levofloxacin is an antibiotic sold under many names, e.g. Quinsair®. It was approved for medical use in the USA in 1996. It is used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, tuberculosis, urinary tract infections, chronic prostatitis, and gastroenteritis. In relation to cystic fibrosis, our AIM tool found the data that levofloxacin inhalation solution can be a safe and effective therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.
Levofloxacin on PubChem
Levofloxacin on DrugBank
Levofloxacin on Wikipedia
Synonyms
LIS, MP-376, Aeroquin
Marketed as
Dietary sources
N/A

C18H20FN3O4
Drug-Mutation Relation
results for 182delT / K710X
See all data on LevofloxacinTreats
Mutation | Link | Tested on | Impact factor | Notes |
---|---|---|---|---|
General effect | A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. | humans | 3.85 | As effective as tobramycin. |
General effect | A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. | humans | 4.73 | |
General effect | Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. | humans | 11.08 |
Does not treat
Mutation | Link | Tested on | Impact factor | Notes |
---|